-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Double glucagon-like peptide-1/glucagon receptor agonist (GLP-1/GCG RA) SAR425899 treatment for 4 weeks has a positive effect on blood sugar control and weight loss in obese type 2 diabetes (T2D) patients.
Double glucagon-like peptide-1/glucagon receptor agonist (GLP-1/GCG RA) SAR425899 treatment for 4 weeks has a positive effect on blood sugar control and weight loss in obese type 2 diabetes (T2D) patients.
In this study, researchers randomly divided 70 overweight to obese T2D patients into 3 groups and received SAR425899 (0.
Blood sugar before and after treatment
Blood sugar before and after treatmentCompared with baseline, at the end of treatment, liraglutide significantly improved the basal insulin action (HOMA2 quantitative median: 35%) and insulin secretion (73%), while SAR42899 only significantly increased insulin secretion ( 125%) .
Liraglutide significantly improved basal insulin action (HOMA2 quantitative median: 35%) and insulin secretion (73%), while SAR42899 only significantly increased insulin secretion (125%)
Postprandial glucose metabolism before and after treatment
Postprandial glucose metabolism before and after treatmentAccording to the quantitative evaluation of OMM, interventions such as SAR425899 and liraglutide significantly enhanced insulin sensitivity (203% and 36%), basic β cell reactivity (67% and 40%), which was higher than basic β cell reactivity (139 % And 69%) .
SAR425899 and liraglutide intervention significantly enhanced insulin sensitivity (203% and 36%), basic β cell reactivity (67% and 40%), higher than basic β cell reactivity (139% and 69%)
In summary, both SAR425899 and liraglutide can improve postprandial blood glucose control in obese type 2 diabetic patients, and moreover.
Both SAR425899 and liraglutide can improve postprandial blood glucose control in obese type 2 diabetic patients, and moreover.
Original source:
Schiavon Michele, Visentin Roberto, Gbel Britta et al.
org/10.
1111/dom.
14394" target="_blank" rel="noopener">Improved Postprandial Glucose Metabolism in Type 2 Diabetes by Dual Glucagon-like Peptide-1 / Glucagon Receptor Agonist SAR425899 in Comparison to Liraglutid
in this message